NCT05383625View on ClinicalTrials.gov

Gardasil Versus Cervarix in the Treatment of Warts

PHASE3CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

September 1, 2020

Primary Completion Date

October 1, 2021

Study Completion Date

December 1, 2021

Conditions
Verruca Viral
Interventions
DRUG

Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine

intralesional 0.1 ml every two weeks

DRUG

Bivalent Human Papilloma Virus Vaccine

Intralesional 0.1 ml every two weeks

DRUG

Saline

intralesional into the largest warts every two weeks

Trial Locations (1)

44511

Dermatology department, Zagazig University Hospitals, Faculty of Medicine, Zagazig University, Zagazig

All Listed Sponsors
lead

Zagazig University

OTHER_GOV

NCT05383625 - Gardasil Versus Cervarix in the Treatment of Warts | Biotech Hunter | Biotech Hunter